IQVIA Holdings Inc. $IQV Shares Sold by The Manufacturers Life Insurance Company

Key Points

• The Manufacturers Life Insurance Company reduced its stake in IQVIA Holdings Inc. by 1.0%, owning 448,853 shares worth approximately $79.1 million after selling 4,370 shares.
• Insider sales included Keriann Cherofsky and Eric Sherbet, who sold 549 and 5,800 shares, respectively, with significant ownership reductions of 15.87% and 17.59% after the transactions.
• IQVIA reported a Q2 earnings per share of $2.81, exceeding estimates, and set FY 2025 guidance at 11.750-12.050 EPS, while analysts project an average price target of $228.62 for its stock.

The Manufacturers Life Insurance Company lessened its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 1.0% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 448,853 shares of the medical research company's stock after selling 4,370 shares during the period. The Manufacturers Life Insurance Company owned 0.26% of IQVIA worth $79,133,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Pacer Advisors Inc. lifted its position in IQVIA by 5,036.1% during the first quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company's stock valued at $153,681,000 after buying an additional 854,732 shares during the period. JPMorgan Chase & Co. increased its holdings in IQVIA by 45.7% in the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock worth $448,686,000 after buying an additional 798,534 shares in the last quarter. D. E. Shaw & Co. Inc. lifted its position in IQVIA by 211.2% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 965,302 shares of the medical research company's stock valued at $189,691,000 after purchasing an additional 655,153 shares during the period. Nuveen LLC purchased a new stake in IQVIA during the first quarter valued at $76,328,000. Finally, Cadian Capital Management LP bought a new position in IQVIA in the fourth quarter valued at about $78,604,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at IQVIA

In related news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider owned 27,178 shares of the company's stock, valued at $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have recently commented on IQV shares. Mizuho boosted their price objective on IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a research report on Friday, July 25th. Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. William Blair reissued an "outperform" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Redburn Partners set a $214.00 price objective on IQVIA in a research note on Wednesday. Finally, Barclays boosted their target price on IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 23rd. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $229.86.

IQVIA Price Performance

IQV traded up $3.09 on Friday, hitting $187.17. 410,122 shares of the company's stock were exchanged, compared to its average volume of 1,919,171. The firm has a 50-day moving average price of $179.28 and a 200-day moving average price of $167.65. The stock has a market cap of $31.82 billion, a price-to-earnings ratio of 27.04, a P/E/G ratio of 2.03 and a beta of 1.32. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $249.43.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.04. The business had revenue of $4.02 billion for the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business's quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.